Fat-loss continues to be a leading focus for anyone committed to healthier living, cutting-edge body composition, or advanced research in peptide therapeutics. Among the wide array of options available, AOD9604—an innovative hgh-fragment—has emerged as a favored candidate for efficient and effortless fat-loss and weight-management. At Oath Research, we’re passionate about quality peptide research and scientific transparency, so let’s explore what makes AOD9604 uniquely compelling for the research community.
Updated on March 4, 2026 — references verified, newer research added.
How Does AOD9604 Drive Fat-Loss?
AOD9604 is a peptide fragment derived from human growth hormone (hGH), specifically the region known as fragment 176-191. Unlike the parent hormone, which influences both growth and anabolic pathways, this smaller hgh-fragment targets fat metabolism and lipolysis exclusively. This means AOD9604 can stimulate the breakdown of stored fat without impacting muscle mass or inducing unwanted anabolic effects.
Researchers have discovered that AOD9604 mimics the natural fat-burning activity of hGH, encouraging the body to release more fat from adipocytes (fat cells) and boost mitochondrial activity. This process, called lipolysis, has been shown to accelerate fat-loss specifically in stubborn fat regions. Foundational research by Ng et al. (2000) demonstrated that oral AOD9604 reduced body weight gain by over 50% in obese Zucker rats over 19 days, with significant increases in adipose tissue lipolysis and no impairment of insulin sensitivity.[1][2] If your research is focused on non-anabolic fat-loss, AOD9604 deserves attention for its tissue specificity and safety profile.
The Unique Non-Anabolic Profile of AOD9604
One of the most important differentiators is that AOD9604 remains non-anabolic. Where traditional hGH may cause broad tissue growth and have unintended consequences, AOD9604 does not. Its mechanism is purely metabolic, making it an exceptional candidate for weight-management research protocols where muscle growth is not desired or could introduce confounding variables.
In research trials, AOD9604 exhibited these key characteristics:
– No increase in IGF-1 levels
– No effect on lean muscle tissue
– Exclusively enhanced fat-loss through increased metabolism and lipolysis
This means research can focus directly on adiposity and metabolic changes without the complications introduced by typical anabolic pathways. Critically, six randomized, double-blind, placebo-controlled human trials in approximately 893 obese adults confirmed that AOD9604 was indistinguishable from placebo in safety and tolerability, with no antibody formation and no treatment-related serious adverse events.[3]
AOD9604 and Metabolism: Scientific Evidence
AOD9604’s ability to modulate metabolism is well-documented. Studies illustrate how this hgh-fragment activates fat breakdown by increasing natural lipolysis while also enhancing fat oxidation. The result? Enhanced metabolic rate and a targeted reduction in body fat.[2]
A pivotal study by Heffernan et al. (2001) documented significant increases in fat catabolism and in vivo fat oxidation in obese mice treated with AOD9604, with no corresponding rise in lean mass or IGF-1. Plasma glycerol levels—an index of lipolysis—were significantly elevated, demonstrating the unique separation between metabolic and growth-promoting pathways that cannot be said for full-length hGH.[2]
For additional reference, see our detailed review of the parent compound, hGH Fragment 176-191.
Mechanism of Action: Beta-3 Adrenergic Receptor Pathway
Research has clarified how AOD9604 exerts its lipolytic effects at the receptor level. Heffernan et al. (2001) demonstrated that AOD9604 upregulates beta-3 adrenergic receptor (beta-3 AR) expression in adipose tissue of obese mice—a finding that helps explain enhanced long-term lipolytic sensitivity. Importantly, AOD9604 does not bind the full hGH receptor, does not induce cell proliferation, and its primary lipolytic mechanism is independent of the traditional hGH receptor pathway. The compound also activates hormone-sensitive lipase and inhibits acetyl-CoA carboxylase in adipocytes, suppressing lipogenesis while promoting fat oxidation.[2]
AOD9604 Fat-Loss: Clinical Trial Evidence and Context
Despite the interest, it’s important to review AOD9604’s clinical development history for a complete picture. Early Phase IIa trial data showed that AOD9604 at 1 mg/day produced 2.6 kg weight loss versus 0.8 kg for placebo over 12 weeks in obese subjects. However, the subsequent 24-week Phase IIb trial in 536 subjects did not achieve statistically significant weight loss compared to placebo, which led Metabolic Pharmaceuticals to terminate the obesity drug development program in 2007.[4]
This clinical history does not diminish AOD9604’s value as a research tool—rather, it underscores the importance of rigorous controls when studying fat-loss compounds. The consistently demonstrated safety profile across human trials, combined with mechanistic evidence in preclinical models, continues to make AOD9604 a uniquely characterized research peptide.
Moreover, since AOD9604 does not appear to impact glucose tolerance, blood hormones (other than those directly involved in metabolism), or cause water retention, it’s considered safe for extended research cycles. In subjects with impaired glucose tolerance, the compound appeared to have a protective effect rather than worsening metabolic status—a key distinction from full hGH.[3]
How Does AOD9604 Compare to Other Fat-Loss and Weight-Management Research Peptides?
In the landscape of peptide-based fat-loss, there are several unique frameworks. AOD9604 is distinct from peptides like CJC-1295 or Ipamorelin, which boost endogenous hGH for global effects, including anabolism. For exclusive focus on fat-loss without muscle growth, AOD9604 stands apart.
Other peptides with fat-loss applications—such as Cagrilintide—act via different pathways, often affecting satiety and calorie intake rather than direct lipolysis. In contrast, AOD9604 is a direct agent of enhanced metabolism and fat oxidation.
To delve deeper into peptide combos focused on tissue recovery and fat regulation, review our BPC-157 and BPC-157/TB-500 Blend.
Weight-Management Benefits Beyond Fat-Loss
Sustainable weight-management is more than just losing fat. For researchers, the lasting impact of any intervention must consider metabolic health, long-term fat distribution, and overall endocrinological safety. By acting as a non-anabolic, metabolic activator, AOD9604 enables studies on long-term body composition modulation with minimal risk of muscle hypertrophy or hormonal imbalance.
AOD9604 also integrates well with interventions designed to maintain energy levels and metabolic activity during caloric restriction—another point in its favor for the study of chronic weight-management strategies.
Regulatory Status and Research Classification
AOD9604 is not FDA-approved for human therapeutic use. Its pharmaceutical development as an obesity drug was discontinued after the Phase IIb trial results. Notably, AOD9604 received FDA GRAS (Generally Recognized as Safe) status for use in foods, drinks, and dietary supplements based on published human safety data from six clinical trials. The compound was also reviewed by the FDA Pharmacy Compounding Advisory Committee (PCAC) in December 2024 regarding its inclusion on the 503A bulk drug substances list. Researchers should consult current regulatory guidance, as the compounding status may evolve.[3]
All products at Oath Research are offered strictly for laboratory research purposes and are not for human or animal use.
Best Practices for AOD9604 Fat-Loss Research
Ensuring experimental rigor is crucial when working with any peptide:
1. Source high-purity peptides from reputable research peptide suppliers such as Oath Research.
2. Utilize research-grade bacteriostatic water (available here) for reconstitution and storage stability.
3. Follow appropriate storage and handling protocols to maintain peptide activity and avoid cross-contamination.
4. Remember: All products are strictly for research purposes and not for human or animal use.
For tips on best practices for other research peptide projects, check our guides at OathPeptides.com.
Fat-Loss Science: AOD9604 Mechanisms and hGH-Fragment Innovation
Peptide science is rapidly evolving. The innovation behind AOD9604 rests on isolating the segment of hGH that strictly influences fat metabolism. By focusing on the 176-191 amino acid fragment, researchers have harnessed the fat-burning, metabolic-activating benefits of hGH while leaving behind the growth-inducing and anabolic effects.
Through binding to fat cell receptors and initiating lipolysis, AOD9604 accelerates triglyceride breakdown—turning stored fat into usable energy. This unique selectivity is both the reason for its safety and its promise for weight-management research applications.
Non-Anabolic Fat-Loss: Why It Matters
Many fat-loss agents fall short because they also trigger muscle gain, water retention, or hormonal changes that can cloud long-term outcomes. AOD9604’s non-anabolic action means researchers can:
– Track changes in fat mass with high specificity
– Avoid confounding muscle growth or edema
– Assess pure metabolic improvements over time
This specificity is ideal for studies where the sole endpoint is change in fat mass and metabolic rate.
Emerging Research: Cartilage and Joint Applications
While AOD9604 is primarily studied for fat-loss and metabolic effects, emerging 2024 peer-reviewed research has identified additional potential applications. Liao et al. (2024) reviewed peptides for cartilage regeneration in osteoarthritis and recognized AOD9604 among candidate disease-modifying treatments. Intra-articular AOD9604 injections were noted to enhance cartilage regeneration in animal models, positioning the peptide alongside BPC-157 and thymosin beta-4 as a multi-use research tool. Earlier work by Kwon et al. (2015) found that combined AOD9604 and hyaluronic acid injections were significantly more effective than either alone for cartilage regeneration in rabbit osteoarthritis models.[5][6]
Integrating AOD9604 in Multi-Peptide Research Protocols
Since many weight-management and fat-loss studies involve synergistic compounds, researchers are experimenting with tailored peptide stacks. For example, pairing a direct metabolic enhancer like AOD9604 with a gut-brain peptide such as Cagrilintide may enable research on combined pathways: appetite regulation and lipid metabolism.
Remember, each peptide presents unique actions, so synergy should be designed according to your research endpoints. For in-depth multi-pathway blends, review “GLOW” or “KLOW” formulas in the Oath Peptides catalog.
Published clinical and preclinical data suggest that AOD9604 is well-tolerated under research conditions. Side effects have been minimal and not significantly different from placebo groups across six randomized trials involving approximately 893 subjects.[3] No growth of organs or tissues has been reported—a key plus for long-term experimental work.
Nevertheless, as with all research compounds:
– Use only under controlled, approved protocols
– Do not use in humans or animals
– Document any unexpected results carefully for review
AOD9604 FAQ
1. What makes AOD9604 different from full-length hGH?
AOD9604 is a fragment of hGH (176-191) that mimics the fat-burning effects but does not cause muscle growth or increase IGF-1 levels. It does not bind the hGH receptor or promote cell proliferation. This makes it ideal for research focusing solely on fat-loss and metabolism without anabolic activity.
2. Is AOD9604 suitable for long-term weight-management studies?
Yes. Its safety profile—validated in six human clinical trials—its non-anabolic nature, and its targeted action on fat metabolism make it appropriate for studies targeting chronic weight-management and sustained fat-loss.
3. What is the best way to reconstitute AOD9604 for research purposes?
We recommend using research-grade bacteriostatic water when preparing AOD9604. Ensure sterility and proper storage at recommended temperatures to maintain stability.
4. Can AOD9604 be combined with other research peptides?
Absolutely. It’s often studied alongside compounds like hGH Fragment 176-191 or Cagrilintide to explore complementary effects on metabolism and appetite. Always design protocols carefully and follow all research regulations.
5. Are there any known safety concerns with AOD9604?
Current human studies in approximately 893 subjects indicate minimal side effects and no anabolic impacts. No antibody formation was detected. However, all use must be confined to laboratory settings, as these products are not for human or animal use.
Conclusion: The Future of Fat-Loss & Weight-Management Research
AOD9604 stands out for its precise, non-anabolic stimulation of fat-loss and metabolism, making it a leading contender for advanced weight-management studies. The decoupling of fat metabolism from muscle growth enables focused research on body fat reduction and metabolic health, advancing our understanding of effective, effortless fat-loss strategies.
Researchers interested in the next generation of peptide therapeutics can explore AOD9604 and related peptides at OathPeptides.com’s AOD9604 product page. For those building synergistic protocols, explore the full research catalog for innovative, rigorously tested compounds.
All products are strictly for research purposes and not for human or animal use.
—
References
1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. (2000). “Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone.” Hormone Research. PMID: 11146367.
2. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. (2001). “Increase of Fat Oxidation and Weight Loss in Obese Mice Caused by Chronic Treatment with Human Growth Hormone or a Modified C-Terminal Fragment.” International Journal of Obesity and Related Metabolic Disorders. PMID: 11673763.
3. Stier H, Vos E, Kenley D. (2013). “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans.” Journal of Endocrinology and Metabolism. Link
4. Misra M. (2013). “Obesity Pharmacotherapy: Current Perspectives and Future Directions.” Current Cardiology Reviews. PMC: PMC3584306.
5. Liao HJ, Chen HT, Chang CH. (2024). “Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis.” Cartilage. PMC: PMC11556548.
6. Kwon DR et al. (2015). “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.” Annals of Clinical and Laboratory Science. PMID: 26275694. Link
7. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. (2001). “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and Beta(3)-AR Knock-Out Mice.” Endocrinology. PMID: 11713213. Link
Discover how NAD+ peptide offers a natural cellular-energy boost by supporting mitochondria, balancing redox processes, and empowering your anti-aging and recovery routines, all while optimizing metabolism for renewed vitality. Unlock effortless wellness and let your cells thrive from the inside out!
Unlock your body’s full potential by harnessing the synergy of a tailored gh-secretagogue stack—designed to amplify your natural gh-pulse for optimal recovery, performance, and lean-mass gains. Discover how combining these compounds can help you maximize research results effortlessly and effectively.
Discover how the AOD9604 peptide is redefining fat-loss and metabolism support—this innovative hgh-fragment targets lipolysis and weight-management, all without the side effects of traditional anabolic agents. If you’re searching for a non-anabolic breakthrough in body composition research, AOD9604 could be the game-changer you’ve been waiting for.
AOD9604 Peptide: Effortless Fat-Loss & Best Weight Management
Fat-loss continues to be a leading focus for anyone committed to healthier living, cutting-edge body composition, or advanced research in peptide therapeutics. Among the wide array of options available, AOD9604—an innovative hgh-fragment—has emerged as a favored candidate for efficient and effortless fat-loss and weight-management. At Oath Research, we’re passionate about quality peptide research and scientific transparency, so let’s explore what makes AOD9604 uniquely compelling for the research community.
Updated on March 4, 2026 — references verified, newer research added.
How Does AOD9604 Drive Fat-Loss?
AOD9604 is a peptide fragment derived from human growth hormone (hGH), specifically the region known as fragment 176-191. Unlike the parent hormone, which influences both growth and anabolic pathways, this smaller hgh-fragment targets fat metabolism and lipolysis exclusively. This means AOD9604 can stimulate the breakdown of stored fat without impacting muscle mass or inducing unwanted anabolic effects.
Researchers have discovered that AOD9604 mimics the natural fat-burning activity of hGH, encouraging the body to release more fat from adipocytes (fat cells) and boost mitochondrial activity. This process, called lipolysis, has been shown to accelerate fat-loss specifically in stubborn fat regions. Foundational research by Ng et al. (2000) demonstrated that oral AOD9604 reduced body weight gain by over 50% in obese Zucker rats over 19 days, with significant increases in adipose tissue lipolysis and no impairment of insulin sensitivity.[1][2] If your research is focused on non-anabolic fat-loss, AOD9604 deserves attention for its tissue specificity and safety profile.
The Unique Non-Anabolic Profile of AOD9604
One of the most important differentiators is that AOD9604 remains non-anabolic. Where traditional hGH may cause broad tissue growth and have unintended consequences, AOD9604 does not. Its mechanism is purely metabolic, making it an exceptional candidate for weight-management research protocols where muscle growth is not desired or could introduce confounding variables.
In research trials, AOD9604 exhibited these key characteristics:
– No increase in IGF-1 levels
– No effect on lean muscle tissue
– Exclusively enhanced fat-loss through increased metabolism and lipolysis
This means research can focus directly on adiposity and metabolic changes without the complications introduced by typical anabolic pathways. Critically, six randomized, double-blind, placebo-controlled human trials in approximately 893 obese adults confirmed that AOD9604 was indistinguishable from placebo in safety and tolerability, with no antibody formation and no treatment-related serious adverse events.[3]
AOD9604 and Metabolism: Scientific Evidence
AOD9604’s ability to modulate metabolism is well-documented. Studies illustrate how this hgh-fragment activates fat breakdown by increasing natural lipolysis while also enhancing fat oxidation. The result? Enhanced metabolic rate and a targeted reduction in body fat.[2]
A pivotal study by Heffernan et al. (2001) documented significant increases in fat catabolism and in vivo fat oxidation in obese mice treated with AOD9604, with no corresponding rise in lean mass or IGF-1. Plasma glycerol levels—an index of lipolysis—were significantly elevated, demonstrating the unique separation between metabolic and growth-promoting pathways that cannot be said for full-length hGH.[2]
For additional reference, see our detailed review of the parent compound, hGH Fragment 176-191.
Mechanism of Action: Beta-3 Adrenergic Receptor Pathway
Research has clarified how AOD9604 exerts its lipolytic effects at the receptor level. Heffernan et al. (2001) demonstrated that AOD9604 upregulates beta-3 adrenergic receptor (beta-3 AR) expression in adipose tissue of obese mice—a finding that helps explain enhanced long-term lipolytic sensitivity. Importantly, AOD9604 does not bind the full hGH receptor, does not induce cell proliferation, and its primary lipolytic mechanism is independent of the traditional hGH receptor pathway. The compound also activates hormone-sensitive lipase and inhibits acetyl-CoA carboxylase in adipocytes, suppressing lipogenesis while promoting fat oxidation.[2]
AOD9604 Fat-Loss: Clinical Trial Evidence and Context
Despite the interest, it’s important to review AOD9604’s clinical development history for a complete picture. Early Phase IIa trial data showed that AOD9604 at 1 mg/day produced 2.6 kg weight loss versus 0.8 kg for placebo over 12 weeks in obese subjects. However, the subsequent 24-week Phase IIb trial in 536 subjects did not achieve statistically significant weight loss compared to placebo, which led Metabolic Pharmaceuticals to terminate the obesity drug development program in 2007.[4]
This clinical history does not diminish AOD9604’s value as a research tool—rather, it underscores the importance of rigorous controls when studying fat-loss compounds. The consistently demonstrated safety profile across human trials, combined with mechanistic evidence in preclinical models, continues to make AOD9604 a uniquely characterized research peptide.
Moreover, since AOD9604 does not appear to impact glucose tolerance, blood hormones (other than those directly involved in metabolism), or cause water retention, it’s considered safe for extended research cycles. In subjects with impaired glucose tolerance, the compound appeared to have a protective effect rather than worsening metabolic status—a key distinction from full hGH.[3]
How Does AOD9604 Compare to Other Fat-Loss and Weight-Management Research Peptides?
In the landscape of peptide-based fat-loss, there are several unique frameworks. AOD9604 is distinct from peptides like CJC-1295 or Ipamorelin, which boost endogenous hGH for global effects, including anabolism. For exclusive focus on fat-loss without muscle growth, AOD9604 stands apart.
Other peptides with fat-loss applications—such as Cagrilintide—act via different pathways, often affecting satiety and calorie intake rather than direct lipolysis. In contrast, AOD9604 is a direct agent of enhanced metabolism and fat oxidation.
To delve deeper into peptide combos focused on tissue recovery and fat regulation, review our BPC-157 and BPC-157/TB-500 Blend.
Weight-Management Benefits Beyond Fat-Loss
Sustainable weight-management is more than just losing fat. For researchers, the lasting impact of any intervention must consider metabolic health, long-term fat distribution, and overall endocrinological safety. By acting as a non-anabolic, metabolic activator, AOD9604 enables studies on long-term body composition modulation with minimal risk of muscle hypertrophy or hormonal imbalance.
AOD9604 also integrates well with interventions designed to maintain energy levels and metabolic activity during caloric restriction—another point in its favor for the study of chronic weight-management strategies.
Regulatory Status and Research Classification
AOD9604 is not FDA-approved for human therapeutic use. Its pharmaceutical development as an obesity drug was discontinued after the Phase IIb trial results. Notably, AOD9604 received FDA GRAS (Generally Recognized as Safe) status for use in foods, drinks, and dietary supplements based on published human safety data from six clinical trials. The compound was also reviewed by the FDA Pharmacy Compounding Advisory Committee (PCAC) in December 2024 regarding its inclusion on the 503A bulk drug substances list. Researchers should consult current regulatory guidance, as the compounding status may evolve.[3]
All products at Oath Research are offered strictly for laboratory research purposes and are not for human or animal use.
Best Practices for AOD9604 Fat-Loss Research
Ensuring experimental rigor is crucial when working with any peptide:
1. Source high-purity peptides from reputable research peptide suppliers such as Oath Research.
2. Utilize research-grade bacteriostatic water (available here) for reconstitution and storage stability.
3. Follow appropriate storage and handling protocols to maintain peptide activity and avoid cross-contamination.
4. Remember: All products are strictly for research purposes and not for human or animal use.
For tips on best practices for other research peptide projects, check our guides at OathPeptides.com.
Fat-Loss Science: AOD9604 Mechanisms and hGH-Fragment Innovation
Peptide science is rapidly evolving. The innovation behind AOD9604 rests on isolating the segment of hGH that strictly influences fat metabolism. By focusing on the 176-191 amino acid fragment, researchers have harnessed the fat-burning, metabolic-activating benefits of hGH while leaving behind the growth-inducing and anabolic effects.
Through binding to fat cell receptors and initiating lipolysis, AOD9604 accelerates triglyceride breakdown—turning stored fat into usable energy. This unique selectivity is both the reason for its safety and its promise for weight-management research applications.
Non-Anabolic Fat-Loss: Why It Matters
Many fat-loss agents fall short because they also trigger muscle gain, water retention, or hormonal changes that can cloud long-term outcomes. AOD9604’s non-anabolic action means researchers can:
– Track changes in fat mass with high specificity
– Avoid confounding muscle growth or edema
– Assess pure metabolic improvements over time
This specificity is ideal for studies where the sole endpoint is change in fat mass and metabolic rate.
Emerging Research: Cartilage and Joint Applications
While AOD9604 is primarily studied for fat-loss and metabolic effects, emerging 2024 peer-reviewed research has identified additional potential applications. Liao et al. (2024) reviewed peptides for cartilage regeneration in osteoarthritis and recognized AOD9604 among candidate disease-modifying treatments. Intra-articular AOD9604 injections were noted to enhance cartilage regeneration in animal models, positioning the peptide alongside BPC-157 and thymosin beta-4 as a multi-use research tool. Earlier work by Kwon et al. (2015) found that combined AOD9604 and hyaluronic acid injections were significantly more effective than either alone for cartilage regeneration in rabbit osteoarthritis models.[5][6]
Integrating AOD9604 in Multi-Peptide Research Protocols
Since many weight-management and fat-loss studies involve synergistic compounds, researchers are experimenting with tailored peptide stacks. For example, pairing a direct metabolic enhancer like AOD9604 with a gut-brain peptide such as Cagrilintide may enable research on combined pathways: appetite regulation and lipid metabolism.
Remember, each peptide presents unique actions, so synergy should be designed according to your research endpoints. For in-depth multi-pathway blends, review “GLOW” or “KLOW” formulas in the Oath Peptides catalog.
Potential Side Effects & Safety Considerations
Published clinical and preclinical data suggest that AOD9604 is well-tolerated under research conditions. Side effects have been minimal and not significantly different from placebo groups across six randomized trials involving approximately 893 subjects.[3] No growth of organs or tissues has been reported—a key plus for long-term experimental work.
Nevertheless, as with all research compounds:
– Use only under controlled, approved protocols
– Do not use in humans or animals
– Document any unexpected results carefully for review
AOD9604 FAQ
1. What makes AOD9604 different from full-length hGH?
AOD9604 is a fragment of hGH (176-191) that mimics the fat-burning effects but does not cause muscle growth or increase IGF-1 levels. It does not bind the hGH receptor or promote cell proliferation. This makes it ideal for research focusing solely on fat-loss and metabolism without anabolic activity.
2. Is AOD9604 suitable for long-term weight-management studies?
Yes. Its safety profile—validated in six human clinical trials—its non-anabolic nature, and its targeted action on fat metabolism make it appropriate for studies targeting chronic weight-management and sustained fat-loss.
3. What is the best way to reconstitute AOD9604 for research purposes?
We recommend using research-grade bacteriostatic water when preparing AOD9604. Ensure sterility and proper storage at recommended temperatures to maintain stability.
4. Can AOD9604 be combined with other research peptides?
Absolutely. It’s often studied alongside compounds like hGH Fragment 176-191 or Cagrilintide to explore complementary effects on metabolism and appetite. Always design protocols carefully and follow all research regulations.
5. Are there any known safety concerns with AOD9604?
Current human studies in approximately 893 subjects indicate minimal side effects and no anabolic impacts. No antibody formation was detected. However, all use must be confined to laboratory settings, as these products are not for human or animal use.
Conclusion: The Future of Fat-Loss & Weight-Management Research
AOD9604 stands out for its precise, non-anabolic stimulation of fat-loss and metabolism, making it a leading contender for advanced weight-management studies. The decoupling of fat metabolism from muscle growth enables focused research on body fat reduction and metabolic health, advancing our understanding of effective, effortless fat-loss strategies.
Researchers interested in the next generation of peptide therapeutics can explore AOD9604 and related peptides at OathPeptides.com’s AOD9604 product page. For those building synergistic protocols, explore the full research catalog for innovative, rigorously tested compounds.
All products are strictly for research purposes and not for human or animal use.
—
References
1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. (2000). “Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone.” Hormone Research. PMID: 11146367.
2. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. (2001). “Increase of Fat Oxidation and Weight Loss in Obese Mice Caused by Chronic Treatment with Human Growth Hormone or a Modified C-Terminal Fragment.” International Journal of Obesity and Related Metabolic Disorders. PMID: 11673763.
3. Stier H, Vos E, Kenley D. (2013). “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans.” Journal of Endocrinology and Metabolism. Link
4. Misra M. (2013). “Obesity Pharmacotherapy: Current Perspectives and Future Directions.” Current Cardiology Reviews. PMC: PMC3584306.
5. Liao HJ, Chen HT, Chang CH. (2024). “Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis.” Cartilage. PMC: PMC11556548.
6. Kwon DR et al. (2015). “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.” Annals of Clinical and Laboratory Science. PMID: 26275694. Link
7. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. (2001). “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and Beta(3)-AR Knock-Out Mice.” Endocrinology. PMID: 11713213. Link
Related Posts
NAD+ Peptide: Effortless Cellular-Energy Boost for Anti-Aging
Discover how NAD+ peptide offers a natural cellular-energy boost by supporting mitochondria, balancing redox processes, and empowering your anti-aging and recovery routines, all while optimizing metabolism for renewed vitality. Unlock effortless wellness and let your cells thrive from the inside out!
Growth Hormone Secretagogue Stack: Synergy for Lean Mass Development
Unlock your body’s full potential by harnessing the synergy of a tailored gh-secretagogue stack—designed to amplify your natural gh-pulse for optimal recovery, performance, and lean-mass gains. Discover how combining these compounds can help you maximize research results effortlessly and effectively.
AOD9604 Peptide: Fat Loss and Metabolic Benefits
Discover how the AOD9604 peptide is redefining fat-loss and metabolism support—this innovative hgh-fragment targets lipolysis and weight-management, all without the side effects of traditional anabolic agents. If you’re searching for a non-anabolic breakthrough in body composition research, AOD9604 could be the game-changer you’ve been waiting for.